The unmet critical need for concussion drug therapies

Neuroscience, a global market overview, including the prevalence, value and future outlook

The editor of Drug Discovery World, Reece Armstrong, speaks to Michael Wyand, CEO of Oxeia about the development of the company’s treatment for concussion (OXE103) and the current lack of effective therapies for #brain injuries.

Results of research at the University of Kansas Medical Center investigating the benefit of Oxeia Biopharmaceuticals’ drug therapy for treating subacute concussion published in the April issue of the American Congress of Rehabilitation Medicine’s journal, Archives of Physical Medicine and Rehabilitation online.

Michael Wyand, PhD, Chief Executive Officer/Director, Oxeia Biopharmaceuticals explains why there’s a need for new drugs to treat traumatic brain injuries. Page 6-7

Most concussions—mild traumatic brain injuries (TBIs)—aren’t treated. Only a fraction of people who experience concussions seek help, and those who do usually are only prescribed rest. For about 20 percent, however, rest doesn’t alleviate the symptoms. Those symptoms may persist for months or years, making daily life difficult. As yet, there is no FDA-approved treatment for mild TBI.

KU Medical Center researcher testing drug to improve concussion symptoms.

Drug tested in pilot study showed promising results in reducing common concussion symptoms.

CONCUSSION DRUG STUDY SHOWS POSITIVE EARLY RESULTS

• Study showed improvement in concussion symptoms in participants receiving OXE103.

• OXE103 pilot Phase 2a trial shows strong potential as an effective treatment for concussion.

• The OXE103 responder rate was 85% vs. a baseline of 33%.

• OXE103 is first in class investigational drug to potentially treat underlying neuro-metabolic and axonal injury in concussion.

• There are currently few studies for and no effective pharmacological FDA-approved treatments for concussion.

A Ph2a Concussion study of Oxeia Biopharmaceutical’s drug, OXE103, showed strong potential as an effective concussion treatment. Dr. Michael Rippee of KUMC Medical Center presented the findings during the ACRM Conference on 10/31

Condition heterogeneity warrants multiple therapeutic approaches, but past failures highlight developmental challenges.

Over $76 billion — that’s the total direct and indirect costs of traumatic brain injuries (TBI) annually. And that’s just the tip of the iceberg.

There are 611 TBI-related hospitalizations and 176 TBI-related deaths each day in the United States. Even more traumatic brain injuries go untreated, with many of those Americans facing injury unable to access medical care.

There is no simple solution, but more attention must be focused on not only understanding why the suicide prevention programs aren’t working, but also developing dramatically improved detection, prevention, and treatment programs and therapies for soldiers.

As part of this equation, we must continue to examine the link between traumatic brain injuries (TBIs) – including mild TBIs (mTBIs) or concussion – and increased risk for suicide. Of the almost 459,000 service members diagnosed with a TBI worldwide between 2000 and Q1 2022, over 82 percent had concussions.

August 3, 2022 (Boston) – Oxeia Biopharmaceuticals Inc., a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, announced today the completion of an interim analysis of its ongoing Phase 2 clinical trial of OXE103 at the University of Kansas Medical Center.

Boston, MA, January 20, 2022 ­– Oxeia Biopharmaceuticals, a clinical stage biotech company conducting Phase 2 clinical trials of OXE103 for treating concussion, today announced two new board members and additions to its executive leadership team. The company also announced its corporate headquarters’ move from San Diego to Boston.

BOSTON, MA (December 21, 2021) ­– Oxeia Biopharmaceuticals Inc., a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury is actively recruiting participants for its ongoing Phase 2 clinical trial of OXE103 at the University of Kansas Medical Center. OXE103 could advance treatment directly addressing the underlying pathology of concussion (mTBI). The program seeks qualified volunteers from the Kansas City area to participate in this study, which could help people with continued symptoms after sustaining a concussion.